Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

This study is testing nab-sirolimus (a drug that blocks an important cancer growth pathway called mTOR) as a first or early-line treatment for people with slow-growing neuroendocrine tumors (NETs) in the gut, lungs, or pancreas who have not previously taken mTOR-blocking drugs. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with a well-differentiated (slow-growing) neuroendocrine tumor in the gastrointestinal tract, lungs, or pancreas that is advanced or has spread - You have received 2 or fewer prior lines of treatment (somatostatin analogs don't count) - You have at least one measurable tumor on imaging - You are in good overall health **You may NOT be eligible if...** - You have previously taken an mTOR inhibitor drug (like everolimus) - You have received more than 2 prior lines of treatment (beyond somatostatin analogs) - You do not have measurable disease on imaging Talk to your doctor to see if this trial is right for you.